CRTC3

Across TCGA pan-cancer cohorts, CRTC3 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of CRTC3’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where CRTC3 RNA is repressed in tumor relative to normal tissue. In most cancer types CRTC3 is over-expressed in tumor, although a few such as THCA and BLCA show the opposite, repressed pattern.

THCA, HNSC, and BLCA are the cancer types where CRTC3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CRTC3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	II,III,IV	−0.586	<.001	10	view →
HNSC	All	II,III,IV	+0.544	<.001	10	view →
BLCA	All	III,IV	−0.693	.009	8	view →
KIRC	Female	All	+0.600	<.001	8	view →
LIHC	All	II,III,IV	+0.602	<.001	6	view →
CHOL	All	All	+1.841	<.001	5	view →
COAD	Female	All	+0.314	.018	5	view →
LUAD	Female	All	−0.435	<.001	4	view →
STAD	Male	II,III,IV	+1.094	.012	2	view →
UCEC	All	All	−0.739	<.001	2	view →
LUSC	Male	All	−0.263	.002	2	view →
KICH	All	All	−0.351	.008	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

CRTC3–THCA

Open the THCA breakdown →